Involvement of Immune Responses in the Efficacy of Cord Blood Cell Therapy for Cerebral Palsy

2015 ◽  
Vol 24 (19) ◽  
pp. 2259-2268 ◽  
Author(s):  
Mino Kang ◽  
Kyunghoon Min ◽  
Joonyoung Jang ◽  
Seung Chan Kim ◽  
Myung Seo Kang ◽  
...  
Keyword(s):  
Cerebral Palsy ◽  
Cell Therapy ◽  
Immune Responses ◽  
Blood Cell ◽  
Cord Blood ◽  
Cord Blood Cell

scholarly journals Single group multisite safety trial of sibling cord blood cell infusion to children with cerebral palsy: study protocol and rationale

BMJ Open ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. e034974
Author(s):  
Kylie Crompton ◽  
Iona Novak ◽  
Michael Fahey ◽  
Nadia Badawi ◽  
Euan Wallace ◽  
...  
Keyword(s):  
Cerebral Palsy ◽  
Blood Cell ◽  
Cord Blood ◽  
Preliminary Evidence ◽  
Fine Motor ◽  
Life Outcomes ◽  
Single Group ◽  
Human Research Ethics ◽  
Cord Blood Cell ◽  
Registration Number

IntroductionCerebral palsy (CP) is the most common physical disability of childhood but has no cure. Stem cells have the potential to improve brain injury and are proposed as a therapy for CP. However, many questions remain unanswered about the most appropriate cell type, timing of infusions, dose required and associated risks. Therefore, human safety and efficacy trials are necessary to progress knowledge in the field.Methods and analysisThis is a single group study with sample size n=12 to investigate safety of single-dose intravenous 12/12 human leucocyte antigen-matched sibling cord blood cell infusion to children with CP aged 1–16 years without immune suppression. The study is similar to a 3+3 design, where the first two groups of participants have severe CP, and the final six participants include children with all motor severities. Children will be monitored for adverse events and the duration that donor cells are detected. Assessments at baseline, 3 and 12 months will investigate safety and preliminary evidence of change in gross motor, fine motor, cognitive and quality of life outcomes.Ethics and disseminationFull approval was obtained from The Royal Children’s Hospital Human Research Ethics Committee, and a clinical trial notification was accepted by Australia’s Therapeutic Goods Administration. Participant guardian informed consent will be obtained before any study procedures. The main results of this study will be submitted for publication in a peer-reviewed journal.Trial registration numberACTRN12616000403437,NCT03087110.

scholarly journals Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Masahiro Tsuji ◽  
Mariko Sawada ◽  
Shinichi Watabe ◽  
Hiroyuki Sano ◽  
Masayo Kanai ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cell Therapy ◽  
Blood Cell ◽  
Cord Blood ◽  
Cord Blood Cell

Cord blood cell therapy trial suspended

2005 ◽  
Vol 23 (12) ◽  
pp. 1455-1456 ◽  
Author(s):  
Cormac Sheridan
Keyword(s):  
Cell Therapy ◽  
Blood Cell ◽  
Cord Blood ◽  
Cord Blood Cell ◽  
Therapy Trial

Advances in umbilical cord blood cell therapy: the present and the future

2017 ◽  
Vol 17 (6) ◽  
pp. 691-699 ◽  
Author(s):  
Sofia Berglund ◽  
Isabelle Magalhaes ◽  
Ahmed Gaballa ◽  
Bruno Vanherberghen ◽  
Michael Uhlin
Keyword(s):  
Cell Therapy ◽  
Blood Cell ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Cord Blood Cell ◽  
Umbilical Cord Blood Cell ◽  
The Future

scholarly journals Could Cord Blood Cell Therapy Reduce Preterm Brain Injury?

2014 ◽  
Vol 5 ◽  
Author(s):  
Jingang Li ◽  
Courtney A. McDonald ◽  
Michael C. Fahey ◽  
Graham Jenkin ◽  
Suzanne L. Miller
Keyword(s):  
Brain Injury ◽  
Cell Therapy ◽  
Blood Cell ◽  
Cord Blood ◽  
Cord Blood Cell
Sign in / Sign up

Export Citation Format

Share Document